Literature DB >> 20112993

Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins.

Sashi G Kasimsetty1, Dobroslawa Bialonska, Muntha K Reddy, Guoyi Ma, Shabana I Khan, Daneel Ferreira.   

Abstract

Pomegranate juice derived ellagitannins and their intestinal bacterial metabolites, urolithins, inhibited TCDD-induced CYP1-mediated EROD activity in vitro with IC(50) values ranging from 56.7 microM for urolithin A to 74.8 microM for urolithin C. These compounds exhibited dose- and time-dependent decreases in cell proliferation and clonogenic efficiency of HT-29 cells. Inhibition of cell proliferation was mediated through cell cycle arrest in the G(0)/G(1) and G(2)/M stages of the cell cycle followed by induction of apoptosis. These results indicate that the ellagitannins and urolithins released in the colon upon consumption of pomegranate juice in considerable amounts could potentially curtail the risk of colon cancer development, by inhibiting cell proliferation and inducing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20112993     DOI: 10.1021/jf903762h

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  32 in total

1.  Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells.

Authors:  Joana Liberal; Anália Carmo; Célia Gomes; Maria Teresa Cruz; Maria Teresa Batista
Journal:  Invest New Drugs       Date:  2017-06-20       Impact factor: 3.850

2.  Gastrointestinal stability of urolithins: an in vitro approach.

Authors:  Pedro Mena; Margherita Dall'Asta; Luca Calani; Furio Brighenti; Daniele Del Rio
Journal:  Eur J Nutr       Date:  2015-10-06       Impact factor: 5.614

Review 3.  Role of pomegranate and citrus fruit juices in colon cancer prevention.

Authors:  Saravana Kumar Jaganathan; Muthu Vignesh Vellayappan; Gayathri Narasimhan; Eko Supriyanto
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

4.  miR-126: A novel regulator in colon cancer.

Authors:  Weina Huang; Jie Lin; Hongxuan Zhang
Journal:  Biomed Rep       Date:  2015-12-02

5.  Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells.

Authors:  Antonio González-Sarrías; Juan Antonio Giménez-Bastida; María Ángeles Núñez-Sánchez; Mar Larrosa; María Teresa García-Conesa; Francisco A Tomás-Barberán; Juan Carlos Espín
Journal:  Eur J Nutr       Date:  2014-04       Impact factor: 5.614

Review 6.  Pomegranate extracts and cancer prevention: molecular and cellular activities.

Authors:  Deeba N Syed; Jean-Christopher Chamcheu; Vaqar M Adhami; Hasan Mukhtar
Journal:  Anticancer Agents Med Chem       Date:  2013-10       Impact factor: 2.505

7.  Bridging cross-cultural gaps: monitoring herbal use during chemotherapy in patients referred to integrative medicine consultation in Israel.

Authors:  Limor Almog; Efraim Lev; Elad Schiff; Shai Linn; Eran Ben-Arye
Journal:  Support Care Cancer       Date:  2014-05-10       Impact factor: 3.603

Review 8.  MicroRNA and cancer chemoprevention.

Authors:  Bin Yi; Gary A Piazza; Xiulan Su; Yaguang Xi
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-26

Review 9.  Bioactive food components and cancer-specific metabonomic profiles.

Authors:  Young S Kim; John A Milner
Journal:  J Biomed Biotechnol       Date:  2010-11-11

10.  Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-α-dependent gene expression.

Authors:  Wei Zhang; Jo-Hsin Chen; Irene Aguilera-Barrantes; Chung-Wai Shiau; Xiugui Sheng; Li-Shu Wang; Gary D Stoner; Yi-Wen Huang
Journal:  Mol Nutr Food Res       Date:  2016-07-25       Impact factor: 5.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.